Unique ID issued by UMIN | UMIN000049692 |
---|---|
Receipt number | R000056572 |
Scientific Title | Basic Research on Microbiome Bank for Manufacturing and Management of Standardized Safe FMT Suspension |
Date of disclosure of the study information | 2022/12/05 |
Last modified on | 2022/12/05 12:09:01 |
Basic Research on Microbiome Bank for Manufacturing and Management of Standardized Safe FMT Suspension
Basic Research on Microbiome Bank
Basic Research on Microbiome Bank for Manufacturing and Management of Standardized Safe FMT Suspension
Basic Research on Microbiome Bank
Japan |
Disorders Associated With Dysbiosis
Gastroenterology |
Others
NO
To promote basic research on microbiome bank to manufacture and manage standardized and safe FMT suspension.
Safety,Efficacy
-
Observational
18 | years-old | <= |
Not applicable |
Male and Female
(1) healthy subjects aged >= 18 years at the time of informed consent;
(2) Those who are able to donate regularly.
(3) Those who are able to undergo regular interviews and screening tests(blood test, stool test, saliva test).
(4) Those who are judged to be eligible in the interview about their health status, medical history, treatment history, vaccination history, and history of high-risk behavior.
(5) Those who have the ability to give consent and can obtain written consent of their own free will.
(1) Suspected infection or carriage of viruses, bacteria, or parasites with the following pathogenicity:
Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis E virus, HIV-1, 2, HTLV-1, Cytomegaloviruses, EB virus, Lues, M. tuberculosis, Clostridioides difficile, Enterohemorrhagic E. coli (O-157), enteroaggregative Escherichia coli (EAEC), Enteropathogenic E. coli (EPEC), Enterotoxigenic E. coli (ETEC), Shiga toxin-producing E. coli (STEC), enteroinvasive Escherichia coli (EIEC), Salmonella, Shigella, Yersinia, Campylobacter, Vibrio parahaemolyticus, Vibrio cholerae, Vibrio vulnificus, Pregenomonas shigeloides, Drug-resistant bacteria, Adenovirus, Norovirus, Rotavirus, Astrovirus, Sapovirus, SARS-CoV-2, Parasites (Strongyloides stercoralis, Giardia lamblia, Cryptosporidium, Entamoeba histolytica, Cyclospora, and other oocysts and parasites)
(2) Those who deviated from the reference values of general peripheral blood test, creatinine, C-reactive protein, AST, ALT, ALP, total bilirubin, and albumin in blood test.
(3) Those who have a positive fecal blood test result from a fecal hemoglobin test.
(4) Persons deemed unsuitable as research subjects by the principal (sub) investigator.
50
1st name | Dai |
Middle name | |
Last name | Ishikawa |
Juntendo University Hospital
Department of Gastroenterology
113-8431
3-1-3 Hongo,Bunkyo-ku,Tokyo
03-3813-3111
dai@juntendo.ac.jp
1st name | Dai |
Middle name | |
Last name | Ishikawa |
Juntendo University Hospital
Department of Gastroenterology
113-8431
3-1-3 Hongo,Bunkyo-ku,Tokyo
03-3813-3111
dai@juntendo.ac.jp
Juntendo University
Metagen Therapeutics, Inc.
Profit organization
Research Ethics Committee Faculty of Medicine, Juntendo University
3-1-3 Hongo,Bunkyo-ku,Tokyo
03-5802-1584
hongo-rinri@juntendo.ac.jp
NO
2022 | Year | 12 | Month | 05 | Day |
Unpublished
Open public recruiting
2022 | Year | 06 | Month | 24 | Day |
2022 | Year | 06 | Month | 17 | Day |
2022 | Year | 06 | Month | 24 | Day |
2024 | Year | 03 | Month | 31 | Day |
-
2022 | Year | 12 | Month | 05 | Day |
2022 | Year | 12 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056572
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |